{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:52:59Z","timestamp":1794048779047,"version":"4.8.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T00:00:00Z","timestamp":1751155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjpad.2025.100266","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T16:37:09Z","timestamp":1751733429000},"page":"100266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6"],"prefix":"10.1016","volume":"12","author":[{"given":"Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel Serap Monkul","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ardayfio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Otero","family":"Svaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Shcherbinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-3921","authenticated-orcid":false,"given":"Scott W.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-235X","authenticated-orcid":false,"given":"Paula M.","family":"Hauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2009-0493","authenticated-orcid":false,"given":"Dawn A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-0942","authenticated-orcid":false,"given":"Stephen","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5090-7886","authenticated-orcid":false,"given":"John R.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100266_bib0001","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","article-title":"Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials","volume":"82","author":"Zimmer","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100266_bib0002","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100266_bib0003","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100266_bib0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.14283\/jpad.2022.129","article-title":"S4-Lecanemab for early Alzheimer's disease: long-term outcomes, predictive biomarkers and novel subcutaneous administration. From: 16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24\u201327, 2023: symposia","volume":"10","author":"Van Dyck","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100266_bib0005","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1002\/psp4.13224","article-title":"Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease","volume":"13","author":"Majid","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.tjpad.2025.100266_bib0006","article-title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","volume":"9","author":"Honig","year":"2023","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.tjpad.2025.100266_bib0007","unstructured":"Gueorguieva I., Chow K., Chua L., et al. Donanemab exposure-response in early symptomatic alzheimer's disease. Alzheimers Dement (N Y) In Press."},{"key":"10.1016\/j.tjpad.2025.100266_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70062","article-title":"Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100266_bib0009","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.tjpad.2025.100266_bib0010","series-title":"AD\/PD\u2122 2025 Alzheimer\u2019s disease and Parkinson\u2019s disease Conference","article-title":"Relationship between amyloid reduction and clinical outcomes following donanemab therapy: insights from the TRAILBLAZER-ALZ 2 phase 3 clinical trial","author":"Lu","year":"2025"},{"key":"10.1016\/j.tjpad.2025.100266_bib0011","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.1016\/j.cell.2023.09.023","article-title":"Accelerating Alzheimer's therapeutic development: the past and future of clinical trials","volume":"186","author":"Boxer","year":"2023","journal-title":"Cell"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:36:56Z","timestamp":1762673816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2274580725002092"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100266","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100266"}}